Background: Studies suggest end-stage renal disease incidence and all-cause mortality rates among patients with chronic kidney disease (CKD) differ by age. The association of diabetes mellitus and ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Share on Pinterest The FDA approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. urbazon/Getty Images The Food and Drug Administration (FDA ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

Research shows that body-weight cycling significantly increases the risk of kidney disease in individuals with Type 1 ...

About 40% of people with type 2 diabetes have chronic kidney disease, according to Novo Nordisk. Type 2 diabetes impacts approximately 37 million adults in the US, the company noted in a press ...